通过一种新型基质选择性小分子抑制剂稳定胰岛素调节的氨基酶的开放构造
Anastasia Mpakali1,2, Galateia Georgaki1,2, Alberto Buson3
1National Centre for Scientific Research Demokritos, Athens, Greece.
Protein science : a publication of the Protein Society
|August 21, 2024
概括
研究人员发现了一种新型的纳米分子抑制剂,用于胰岛素调节的氨基酶 (IRAP). 这种pyrazolylpyrimidine化合物独特地准一个开放的酶构造,为IRAP活动调节提供了一个新的策略.
科学领域:
- 生物化学 生物化学
- 酶学 是一种酶学.
- 药物发现 药物发现 药物发现
背景情况:
- 胰岛素调控氨基酶 (IRAP) 是一种具有重要的生物作用的关键酶.
- 对治疗药物开发来说,IRAP是一个有吸引力的目标.
研究的目的:
- 发现和描述一种新的,强效的,选择性的IRAP抑制剂.
- 阐明IRAP抑制的作用机制和结构基础.
主要方法:
- 在子选和药物化学优化.
- 酶动力学,选择性分析和细胞分析.
- 对IRAP抑制剂复合物的X射线结晶学.
主要成果:
- 一个pyrazolylpyrimidine支架产生了一个具有高选择性的纳米分子IRAP抑制剂.
- 该抑制剂对典型基质表现出一种不具有竞争力的机制,但对加工具有不寻常的选择性.
- 晶体结构揭示了 (II) 参与和结合开放的酶构成,阻止过渡到活性封闭状态.
结论:
- 这种发现的化合物是第一个使用特定构造机制的活性位点导向IRAP抑制剂.
- 这项工作为IRAP的催化循环和构造动态提供了洞察力.
- 阻断酶的结构重组代表了调节IRAP活动的新方法.
更多相关视频
11:01Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
Published on: November 23, 2016
9.6K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
Glucagon-like Receptor Agonists
308
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
308
Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
Enzymes
81.2K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
81.2K
Enzyme Inhibition
78.1K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.1K
Insulin: Biosynthesis, Chemistry, and Preparation
365
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
365
Allosteric Regulation
57.8K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.8K
